Three previous meta-analyses (Camilli et al., 2021; Yan et al., 2021; Zhao et al., 2021b) demonstrated that the combination therapy of SGLT2 inhibitors and RAAS inhibitors [such as angiotensin receptor neprilysin inhibitors (Camilli et al., 2021; Yan et al., 2021) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (Zhao et al., 2021b)] led to greater cardiorenal benefits than SGLT2 inhibitor monotherapy in patients with heart failure or T2D. Here, SLC5A2 is linked to heart failure.